Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11237-11251

  Liu, Yi Lun ^a   Lai, Fritz ^a   Wilmott, James S ^b   Yan, Xu Guang ^a   Liu, Xiao Ying ^a   Luan, Qi ^a   Guo, Su Tang ^a,c   Jiang, Chen Chen ^d   Tseng, Hsin Yi ^a   Scolyer, Richard A ^b   Jin, Lei ^d   Zhang, Xu Dong ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c SHANXI CANCER HOSPITAL   (China)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Autophagy; CREB; MEK ERK; Melanoma; Noxa

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN NOXA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ENZYMOLOGY; GENETICS; MELANOCYTE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

AUTOPHAGY; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MELANOCYTES; MELANOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84917677555     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2616     Document Type: Article

References (67)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-954.
2. Platz A, Egyhazi S, Ringborg U and Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008; 1(4):395-405.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516.
4. Houslay MD. Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell. 2011; 19(1):3-4.
5. Ribas A and Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011; 8(7):426-433.
6. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD and Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 2007; 13(16):4934-4942.
7. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A and Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008; 118(11):3651-3659.
8. Martinou JC and Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001; 2(1):63-67.
9. Adams JM and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-1326.
10. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF and Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol. 2007; 20(4):416- 426.
11. Hersey P, Zhang XD and Mhaidat N. Overcoming resistance to apoptosis in cancer therapy. Adv Exp Med Biol. 2008; 615:105-126.
12. Dai DL, Wang Y, Liu M, Martinka M and Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol. 2008; 128(2):403-407.
13. Karst AM, Dai DL, Martinka M and Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene. 2005; 24(6):1111-1116.
14. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ and Green DR. The BCL-2 family reunion. Mol Cell. 2010; 37(3):299-310.
15. Rabinowitz JD and White E. Autophagy and metabolism. Science. 2010; 330(6009):1344-1348.
16. Heath-Engel HM, Chang NC and Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene. 2008; 27(50):6419- 6433.
17. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8(4):445-544.
18. Kondo Y, Kanzawa T, Sawaya R and Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005; 5(9):726-734.
19. Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L and Zhang XD. Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1. Autophagy. 2012; 8(1):109-121.
20. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia- Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, Moreau K, Narayanan U, Renna M, Siddiqi FH, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010; 90(4):1383-1435.
21. Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H and Liu Z. Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy. 2014; 10(2):257-268.
22. Byfield MP, Murray JT and Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem. 2005; 280(38):33076-33082.
23. Elgendy M, Sheridan C, Brumatti G and Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell. 2011; 42(1):23-35.
24. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403.
25. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, de Bock CE, Hersey P and Zhang XD. Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene. 2011; 30(34):3716-3726.
26. Puthalakath H, O'Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm- Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P and Strasser A. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell. 2007; 129(7):1337-1349.
27. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000; 288(5468):1053-1058.
28. Tseng HY, Jiang CC, Croft A, Tay KH, Thorne RF, Yang F, Liu H, Hersey P and Zhang XD. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther. 2010; 9(12):3363-3374.
29. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP and Hersey P. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res. 2008; 14(6):1659-1668.
30. Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CY, et al. PI(4,5) P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun. 2013; 4:1508.
31. Basile KJ and Aplin AE. Downregulation of Noxa by RAF/ MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012; 2(6):726- 735.
32. Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-430.
33. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464(7287):431-435.
34. Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, Tseng HY, Jin L, Rizos H, Hersey P and Zhang XD. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J Invest Dermatol. 2014; 134(2):488-497.
35. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, Hersey P, Zhang XD and Wu M. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A. 2011; 108(38):15840-15845.
36. Hershko T and Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem. 2004; 279(10):8627-8634.
37. Mei Y, Xie C, Xie W, Tian X, Li M and Wu M. Noxa/Mcl- 1 balance regulates susceptibility of cells to camptothecininduced apoptosis. Neoplasia. 2007; 9(10):871-881.
38. Lallemand C, Blanchard B, Palmieri M, Lebon P, May E and Tovey MG. Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB. Oncogene. 2007; 26(3):328-338.
39. Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ and Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol. 2010; 130(6):1657- 1667.
40. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R and Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998; 23(1):33- 42.
41. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD and Hersey P. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stressinduced apoptosis. Cancer Res. 2007; 67(20):9750-9761.
42. Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF, Allen J, Hersey P and Zhang XD. Upregulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res. 2008; 68(16):6708-6717.
43. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
44. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
45. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014; 74(3):647-651.
46. Guo JY, Xia B and White E. Autophagy-mediated tumor promotion. Cell. 2013; 155(6):1216-1219.
47. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007; 67(8):3496- 3499.
48. Wang G, Yang ZQ and Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res. 2010; 2(1):65-74.
49. Izuishi K, Kato K, Ogura T, Kinoshita T and Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000; 60(21):6201-6207.
50. Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, Thorburn A and He YY. Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci U S A. 2014; 111(25):9241-9246.
51. Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford RF, Zhang XD and Rizos H. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene. 2014; 33(9):1158-1166.
52. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK and Allen JD. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res. 2012; 18(3):783-795.
53. Pang X, Zhang J, Lopez H, Wang Y, Li W, O'Neill KL, Evans JJ, George NM, Long J, Chen Y and Luo X. The Carboxyl-terminal Tail of Noxa Protein Regulates the Stability of Noxa and Mcl-1. J Biol Chem. 2014; 289(25):17802-17811.
54. Jiang CC, Wroblewski D, Yang F, Hersey P and Zhang XD. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia. 2009; 11(9):945-955.
55. Dobroff AS, Wang H, Melnikova VO, Villares GJ, Zigler M, Huang L and Bar-Eli M. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem. 2009; 284(38):26194-26206.
56. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y and Wu M. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis. 2013; 4:e914.
57. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE and Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013; 504(7478):138-142.
58. Goodall ML, Wang T, Martin KR, Kortus MG, Kauffman AL, Trent JM, Gately S and MacKeigan JP. Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. Autophagy. 2014; 10(6):1120-1136.
59. Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH, Foreman NK and Thorburn A. Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors. Cancer Discov. 2014; 4(7):773-780.
60. Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, Liu T, Guo ST, Verrills NM, Hersey P and Zhang XD. Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death Dis. 2012; 3:e337.
61. Nguyen T, Zhang XD and Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res. 2001; 7(3 Suppl):966s-973s.
62. Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF and Hersey P. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol. 2010; 23(1):45-53.
63. Dong L, Jin L, Tseng HY, Wang CY, Wilmott JS, Yosufi B, Yan XG, Jiang CC, Scolyer RA, Zhang XD and Guo ST. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene. 2013.
64. Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, Chi MN, Tseng HY, Farrelly M, Atmadibrata B, Norman J, Liu T, Hersey P and Zhang XD. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death Dis. 2013; 4:e655.
65. Tseng HY, Chen LH, Ye Y, Tay KH, Jiang CC, Guo ST, Jin L, Hersey P and Zhang XD. The melanomaassociated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis. 2012; 33(10):1871-1881.
66. Jiang CC, Croft A, Tseng HY, Guo ST, Jin L, Hersey P and Zhang XD. Repression of microRNA-768-3p by MEK/ ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene. 2014; 33(20):2577-2588.
67. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M, Bataille R and Amiot M. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007; 67(11):5418-5424.